tiprankstipranks
Advertisement
Advertisement

AKTS Stock Latest News

Aktis Oncology initiated with a Strong Buy at Raymond James
The FlyAktis Oncology initiated with a Strong Buy at Raymond James
17d ago
AKTS
Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright
PremiumThe Fly
Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright
1M ago
AKTS
Early Clinical Data and Differentiated Miniprotein Platform Underpin Buy Rating on Aktis for B7-H3 Radiopharmaceutical in mCRPC
PremiumRatings
Early Clinical Data and Differentiated Miniprotein Platform Underpin Buy Rating on Aktis for B7-H3 Radiopharmaceutical in mCRPC
1M ago
AKTS
Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update
PremiumRatings
Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update
1M ago
AKTS
Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity
PremiumRatings
Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity
1M ago
AKTS
Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and Multiple High-Value Oncology Targets
PremiumRatingsAktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and Multiple High-Value Oncology Targets
2M ago
AKTS
Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M
Premium
The Fly
Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M
2M ago
AKTS
Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and mCRPC Opportunity for AKY‑2519
Premium
Ratings
Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and mCRPC Opportunity for AKY‑2519
2M ago
AKTS
Aktis Oncology initiates clinical trial of AKY-25191
PremiumThe Fly
Aktis Oncology initiates clinical trial of AKY-25191
2M ago
AKTS
Aktis Oncology initiated with an Outperform at William Blair
PremiumThe Fly
Aktis Oncology initiated with an Outperform at William Blair
2M ago
AKTS
Aktis Oncology appoints Gormley as independent director of Board of Directors
PremiumThe Fly
Aktis Oncology appoints Gormley as independent director of Board of Directors
3M ago
AKTS
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target
PremiumRatings
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target
3M ago
AKTS
Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright
PremiumThe FlyAktis Oncology price target raised to $33 from $30 at H.C. Wainwright
3M ago
AKTS
Aktis Oncology announces FDA clearance of AKY-25191 trial
Premium
The Fly
Aktis Oncology announces FDA clearance of AKY-25191 trial
3M ago
AKTS
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
4M ago
MWH
AKTS
Aktis Oncology initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Aktis Oncology initiated with a Buy at H.C. Wainwright
4M ago
AKTS
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors
PremiumCompany Announcements
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors
4M ago
AKTS
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target
PremiumRatings
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target
4M ago
AKTS
Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189
PremiumThe Fly
Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189
4M ago
AKTS
Adobe downgraded, Palantir upgraded: Wall Street’s top analyst calls
PremiumThe FlyAdobe downgraded, Palantir upgraded: Wall Street’s top analyst calls
5M ago
V
MA
Aktis Oncology initiated with an Outperform at Leerink
Premium
The Fly
Aktis Oncology initiated with an Outperform at Leerink
5M ago
AKTS
Aktis Oncology initiated with a Buy at BofA
Premium
The Fly
Aktis Oncology initiated with a Buy at BofA
5M ago
AKTS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >